Enterprise Value
7.803M
Cash
6.939M
Avg Qtr Burn
-9.311M
Short % of Float
4.54%
Insider Ownership
1.66%
Institutional Own.
16.43%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Larazotide Details COVID-19 | Phase 2 Data readout | |
Vurolenatide (NM-002) (GLP-1 Agonist) Details Rare diseases, Bowel disorder | Phase 2 Initiation | |
Larazotide Details Celiac disease, Autoimmune disease | Failed Discontinued |